Lenvatinib + Pembrolizumab
Various Solid Tumors
Phase 3 / MarketedActive (label expansions)
Key Facts
About Eisai
Eisai is a fully integrated, patient-centric biopharmaceutical company with a mission to give first thought to patients and their families. Its strategic focus on neurology and oncology has yielded landmark achievements, most notably the commercialization of the first disease-modifying Alzheimer's therapy, LEQEMBI, in partnership with Biogen. The company complements its commercial success with a deep, long-standing commitment to sustainability and global health, distributing billions of treatments for neglected tropical diseases. Financially robust and strategically disciplined, Eisai is leveraging its neuroscience leadership to expand its oncology portfolio and solidify its long-term growth trajectory.
View full company profileOther Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| Jemperli (dostarlimab) combinations | GSK | Phase 3 |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| PD-1/PD-L1 Inhibitor | PeptiDream | Phase 1 |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |
| Early I-O Pipeline | Ipsen | Pre-clinical / Phase 1 |